Bank of China International (BOCI) published a research report stating that WuXi AppTec (02359.HK) delivered strong first-half performance, with solid revenue and net profit growth, margin expansion, and outstanding performance from its TIDES business. Meanwhile, resilient growth in its chemistry business helped offset weakness in its clinical CRO and testing businesses. Management raised its 2025 revenue guidance to between RMB 42.5 billion and RMB 43.5 billion, representing a 13% to 17% increase in continuing operations. Capital expenditure remained unchanged at RMB 7 billion to 8 billion. BOC International raised its earnings forecasts for WuXi AppTec by 15% and 22% for this year and next year, respectively, and raised its target price from HK$81 to HK$122. The company maintained its "Buy" rating.